Vaxxas licenses RSV vaccine candidate
Needle free biotechnology company Vaxxas has announced that the United States National Institutes of Health (NIH) has granted the company a licence to a vaccine antigen candidate (DS2), designed for use in prophylactic vaccines against Respiratory Syncytial Virus (RSV). RSV is a common contagious virus affecting the lungs and breathing passages which causes an estimated…